LLLaura Lückemann

Laura Lückemann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laura Lückemann has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Martin Hadamitzky

    Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

    11 shared publications
  • Manfred Schedlowski

    Institute of Medical Psychology and Behavioral Immunobiology, Center for Translational Neuro‐ and Behavioral Sciences (C‐TNBS), University Hospital Essen University of Duisburg‐Essen Essen Germany

    6 shared publications
  • Manfred Schedlowski

    Institute of Medical Psychology and Behavioral Immunobiology, Center for Translational Neuro- and Behavioral Sciences, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; Osher Center for Integrative Health, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

    6 shared publications
  • Harald Engler

    Institute of Medical Psychology and Behavioral Immunobiology, Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University of Duisburg-Essen, Essen, Germany

    4 shared publications
  • Meike Unteroberdörster

    Department of Neurosurgery, University Hospital Essen, University of Duisburg-Essen, 45122, Essen, Germany; Department of Neurosurgery, Charité Universitätsmedizin, 10117, Berlin, Germany

    4 shared publications
  • Gustavo Pacheco-López

    Health Sciences Department, Biological and Health Sciences Division, Campus Lerma, Metropolitan Autonomous University (UAM), Lerma 52005 Mexico

    2 shared publications

Latest Publications

  • Konditionierung des Immunsystems – Schon klinisch nutzbar?

    by M. Jakobs, M. Hadamitzky, M. Schedlowski, L. Heiß-Lückemann


  • Open Access

    Taste‐Associative Learning in Rats: Conditioned Immunosuppression with Cyclosporine A to Study the Neuro‐Immune Network

    by Stephan Leisengang, Manfred Schedlowski, Martin Hadamitzky, Laura Lückemann

    The pharmacological effects of an immunosuppressive drug, such as cyclosporine A (CsA), can be learned and retrieved by humans and animals when applying associative learning paradigms. This principle is based on Pavlovian conditioning, in which repeated presentation of an “unconditioned stimulus” (US; here, the drug CsA) is paired with exposure to a “conditioned stimulus” (CS; here, the novel taste of saccharin). Re‐exposure to the CS at a later time leads to an avoidance behavior. Concomitantly, using this paradigm, animals exposed to the CS (saccharin) display immunosuppression, reflected by reduced splenic T‐cell proliferation and diminished interleukin‐2 and interferon‐γ expression and release in ex vivo cultured splenocytes, mimicking the pharmacological effects of the US (CsA). Notably, this paradigm of taste‐immune associative learning demonstrates the impressive abilities of the brain to detect and store information about an organism's immunological status and to retrieve this information, thereby modulating immunological functions via endogenous pathways. Moreover, conditioned pharmacological effects, obtained by means of associative learning, have been successfully implemented as controlled drug‐dose reduction strategies as a supportive treatment option to optimize pharmacological treatment effects for patients’ benefit. However, our knowledge about the underlying neurobiological and immunological mechanisms mediating such learned immunomodulatory effects is still limited. A reliable animal model of taste‐immune associative learning can provide novel insights into peripheral and central nervous processes. In this article, we describe protocols that focus on the basic taste‐immune associative learning paradigm with CsA and saccharin in rats, where conditioned peripheral immunosuppression is determined in ex vivo cultured splenocytes. The behavioral protocol is reliable and adaptable and may pave the road for future studies using taste‐immune associative learning paradigms to gain deeper insight into brain‐to‐immune‐system communication. © 2022 The Authors. Current Protocols published by Wiley Periodicals LLC.Basic Protocol 1: Taste‐immune associative learning with cyclosporine ABasic Protocol 2: Splenocyte isolation and cultivation to study stimulation‐induced cytokine production


  • A step-by-step guide for microsurgical collection of uncontaminated cerebrospinal fluid from rat cisterna magna

    by Lennart Barthel, Harald Engler, Martin Hadamitzky, Laura Lückemann, Ulrich Sure, Manfred Schedlowski, Susann Hetze


  • Neurobehavioral effects in rats with experimentally induced glioblastoma after treatment with the mTOR-inhibitor rapamycin

    by Meike Unteroberdörster, Arne Herring, Ivo Bendix, Laura Lückemann, Jasmin Petschulat, Ulrich Sure, Kathy Keyvani, Susann Hetze, Manfred Schedlowski, Martin Hadamitzky


  • Open Access

    How learning shapes immunity

    by Martin Hadamitzky, Laura Lückemann, Manfred Schedlowski, Harald Engler

    Experimental studies in rodents and humans have convincingly demonstrated that immune functions can be modulated by associative learning processes. We have established a conditioned taste avoidance (CTA) paradigm in rats by pairing a novel taste (conditioned stimulus, CS) with an injection of the immunosuppressive drug cyclosporine A (CsA; unconditioned stimulus, US). Re-exposure to the CS results in a pronounced CTA and, more importantly, in a selective suppression of specific T-cell functions, mimicking the drugs’ effects. To provide a basis for using learned immunosuppressive strategies in clinical situations, we are currently investigating the neurobiological mechanisms underlying the extinction of conditioned immunosuppressive responses and the generalizability of our findings to other immunomodulatory drugs.

  • Learned Immunosuppressive Placebo Response Attenuates Disease Progression in a Rodent Model of Rheumatoid Arthritis

    by Laura Lückemann, Hubert Stangl, Rainer H. Straub, Manfred Schedlowski, Martin Hadamitzky

    Objective: Patients with chronic inflammatory autoimmune diseases benefit from a broad spectrum of immunosuppressive and antiproliferative medication available today. However, nearly all of these therapeutic compounds have unwanted toxic side effects. Recent knowledge about the neurobiology of placebo responses indicates that associative learning procedures can be utilized for dose reduction in immunopharmacotherapy while simultaneously maintaining treatment efficacy. This study was undertaken to examine whether and to what extent a 75% reduction of pharmacologic medication in combination with learned immunosuppression affects the clinical outcome in a rodent model of type II collagen–induced arthritis.Methods: An established protocol of taste‐immune conditioning was applied in a disease model of chronic inflammatory autoimmune disease (type II collagen–induced arthritis) in rats, where a novel taste (saccharin; conditioned stimulus [CS]) was paired with an injection of the immunosuppressive drug cyclosporin A (CSA) (unconditioned stimulus [US]). Following conditioning with 3 CS/US pairings (acquisition), the animals were immunized with type II collagen and Freund's incomplete adjuvant. Fourteen days later, at the first occurrence of clinical symptoms, retrieval was started by presenting the CS together with low‐dose CSA as reminder cues to prevent the conditioned response from being extinguished.Results: This “memory‐updating” procedure stabilized the learned immune response and significantly suppressed disease progression in immunized rats. Clinical arthritis score and histologic inflammatory symptoms (both P < 0.05) were significantly diminished by learned immunosuppression in combination with low‐dose CSA (25% of the full therapeutic dose) via β‐adrenoceptor–dependent mechanisms, to the same extent as with full‐dose (100%) pharmacologic treatment.Conclusion: These results indicate that learned immunosuppression appears to be mediated via β‐adrenoceptors and might be beneficial as a supportive regimen in the treatment of chronic inflammatory autoimmune diseases by diminishing disease exacerbation.


  • Behavioral conditioning of anti-proliferative and immunosuppressive properties of the mTOR inhibitor rapamycin

    by Laura Lückemann, Meike Unteroberdörster, Elian Martinez Gomez, Manfred Schedlowski, Martin Hadamitzky


  • Open Access

    Repeated Systemic Treatment with Rapamycin Affects Behavior and Amygdala Protein Expression in Rats

    by Martin Hadamitzky, Arne Herring, Julia Kirchhof, Ivo Bendix, Matthew J Haight, Kathy Keyvani, Laura Lückemann, Meike Unteroberdörster, Manfred Schedlowski

    Clinical data indicate that therapy with small-molecule immunosuppressive drugs is frequently accompanied by an incidence rate of neuropsychiatric symptoms. In the current approach, we investigated in rats whether repeated administration of rapamycin, reflecting clinical conditions of patients undergoing therapy with this mammalian target of rapamycin inhibitor, precipitates changes in neurobehavioral functioning. Male adult Dark Agouti rats were daily treated with i.p. injections of rapamycin (1, 3 mg/kg) or vehicle for 8 days. On days 6 and 7, respectively, behavioral performance in the Elevated Plus-Maze and the Open-Field Test was evaluated. One day later, amygdala tissue and blood samples were taken to analyze protein expression ex vivo. The results show that animals treated with rapamycin displayed alterations in Elevated Plus-Maze performance with more pronounced effects in the higher dose group. Besides, an increase in glucocorticoid receptor density in the amygdala was seen in both treatment groups even though p-p70 ribosomal S6 kinase alpha, a marker for mammalian target of rapamycin functioning, was not affected. Protein level of the neuronal activity marker c-Fos was again only elevated in the higher dose group. Importantly, effects occurred in the absence of acute peripheral neuroendocrine changes. Our findings indicate that anxiety-related behavior following rapamycin treatment was not directly attributed to mTOR-dependent mechanisms or stress but rather due to hyperexcitability of the amygdala together with glucocorticoid receptor-regulated mechanism(s) in this brain region. Together, the present results support the contention that subchronic treatment with rapamycin may induce neurobehavioral alterations in healthy, naive subjects. We here provide novel insights in central effects of systemic rapamycin in otherwise healthy subjects but also raise the question whether therapy with this drug may have detrimental effects on patients’ neuropsychological functioning during immune therapy.


  • Applications and limitations of behaviorally conditioned immunopharmacological responses

    by Laura Lückemann, Meike Unteroberdörster, Julia Kirchhof, Manfred Schedlowski, Martin Hadamitzky


  • Oxytocin’s role on the cardiorespiratory activity of endotoxemic rats

    by Ana Rosa Elorza-Ávila, José Javier Reyes-Lagos, Martin Hadamitzky, Miguel Ángel Peña-Castillo, Juan Carlos Echeverría, María del Rocío Ortiz-Pedroza, Laura Lückemann, Manfred Schedlowski, Gustavo Pacheco-López